A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas: Subanalysis of J-CROS 1402 HN

the Japan Carbon-Ion Radiation Oncology Study Group

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A retrospective multicenter study was carried out to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at four Japanese institutions were analyzed. Thirty-three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types. Three patients (4%) had T1 disease, 8 (12%) had T2, 25 (36%) had T3, and 33 (48%) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow-up period was 32.7 months. The 3-year local control rate and overall survival rate were 81% and 94%, respectively. Regarding acute toxicities, seven patients had grade 3 mucositis and seven had grade 3 dermatitis. Regarding late toxicities, one patient had grade 3 dysphagia and one had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon-ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.

Original languageEnglish
Pages (from-to)1576-1582
Number of pages7
JournalCancer Science
Volume109
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Heavy Ion Radiotherapy
Radiation Oncology
Salivary Glands
Multicenter Studies
Japan
Carbon
Retrospective Studies
Ions
Carcinoma
Relative Biological Effectiveness
Mucoepidermoid Carcinoma
Adenoid Cystic Carcinoma
Brain Abscess
Mucositis
Dermatitis
Deglutition Disorders
Tumor Burden
Neck
Survival Rate
Head

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas : Subanalysis of J-CROS 1402 HN. / the Japan Carbon-Ion Radiation Oncology Study Group.

In: Cancer Science, Vol. 109, No. 5, 05.2018, p. 1576-1582.

Research output: Contribution to journalArticle

the Japan Carbon-Ion Radiation Oncology Study Group. / A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas : Subanalysis of J-CROS 1402 HN. In: Cancer Science. 2018 ; Vol. 109, No. 5. pp. 1576-1582.
@article{1f6b39a960cf44d6b42ff4bfe0d606b6,
title = "A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas: Subanalysis of J-CROS 1402 HN",
abstract = "A retrospective multicenter study was carried out to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at four Japanese institutions were analyzed. Thirty-three patients (48{\%}) had adenoid cystic carcinomas, 10 (14{\%}) had mucoepidermoid carcinomas, and 26 (38{\%}) had other disease types. Three patients (4{\%}) had T1 disease, 8 (12{\%}) had T2, 25 (36{\%}) had T3, and 33 (48{\%}) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow-up period was 32.7 months. The 3-year local control rate and overall survival rate were 81{\%} and 94{\%}, respectively. Regarding acute toxicities, seven patients had grade 3 mucositis and seven had grade 3 dermatitis. Regarding late toxicities, one patient had grade 3 dysphagia and one had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon-ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.",
author = "{the Japan Carbon-Ion Radiation Oncology Study Group} and Kazuhiko Hayashi and Masashi Koto and Yusuke Demizu and Saitoh, {Jun Ichi} and Hiroaki Suefuji and Tomoaki Okimoto and Tatsuya Ohno and Yoshiyuki Shioyama and Ryo Takagi and Hiroaki Ikawa and Kenji Nemoto and Takashi Nakano and Tadashi Kamada",
year = "2018",
month = "5",
doi = "10.1111/cas.13558",
language = "English",
volume = "109",
pages = "1576--1582",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas

T2 - Subanalysis of J-CROS 1402 HN

AU - the Japan Carbon-Ion Radiation Oncology Study Group

AU - Hayashi, Kazuhiko

AU - Koto, Masashi

AU - Demizu, Yusuke

AU - Saitoh, Jun Ichi

AU - Suefuji, Hiroaki

AU - Okimoto, Tomoaki

AU - Ohno, Tatsuya

AU - Shioyama, Yoshiyuki

AU - Takagi, Ryo

AU - Ikawa, Hiroaki

AU - Nemoto, Kenji

AU - Nakano, Takashi

AU - Kamada, Tadashi

PY - 2018/5

Y1 - 2018/5

N2 - A retrospective multicenter study was carried out to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at four Japanese institutions were analyzed. Thirty-three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types. Three patients (4%) had T1 disease, 8 (12%) had T2, 25 (36%) had T3, and 33 (48%) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow-up period was 32.7 months. The 3-year local control rate and overall survival rate were 81% and 94%, respectively. Regarding acute toxicities, seven patients had grade 3 mucositis and seven had grade 3 dermatitis. Regarding late toxicities, one patient had grade 3 dysphagia and one had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon-ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.

AB - A retrospective multicenter study was carried out to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at four Japanese institutions were analyzed. Thirty-three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types. Three patients (4%) had T1 disease, 8 (12%) had T2, 25 (36%) had T3, and 33 (48%) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow-up period was 32.7 months. The 3-year local control rate and overall survival rate were 81% and 94%, respectively. Regarding acute toxicities, seven patients had grade 3 mucositis and seven had grade 3 dermatitis. Regarding late toxicities, one patient had grade 3 dysphagia and one had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon-ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=85046007663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046007663&partnerID=8YFLogxK

U2 - 10.1111/cas.13558

DO - 10.1111/cas.13558

M3 - Article

C2 - 29493851

AN - SCOPUS:85046007663

VL - 109

SP - 1576

EP - 1582

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -